Serum level of lactate dehydrogenase is a useful clinical marker to monitor progressive multiple myeloma diseases: A case report;Progresif multiple myeloma hastali{dotless}ǧi{dotless}nda serum laktat dehidrogenaz düzeyi kullani{dotless}şli{dotless} bir klinik belirteçdir: Bir olgu sunumu

Turkish Journal of Hematology

Volumn 31, Issue 1, 2014, Pages 84-87

  Teke, Hava Üsküdar ^a   Başak, Mustafa ^a   Teke, Deniz ^a   Kanbay, Mehmet ^a  

^a Kayseri Education and Research Hospital   (Turkey)

Author keywords

LDH; Multiple myeloma; Prognosis

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CD38 ANTIGEN; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN KAPPA CHAIN; LACTATE DEHYDROGENASE; MELPHALAN; PREDNISOLONE; SYNDECAN 1;

ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; ECHOGRAPHY; FATIGUE; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LEUKOPENIA; LUNG EDEMA; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMACYTOMA; PROTEIN ELECTROPHORESIS; UNCONSCIOUSNESS; VERY ELDERLY; X RAY;

EID: 84905858435     PISSN: 13007777     EISSN: 13085263     Source Type: Journal    
DOI: 10.4274/Tjh.2012.0044     Document Type: Article

References (10)

1. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol 2005;23:6281.
2. Simonsson B, Brenning G, Kallander C, Ahre A. Prognostic value of serum lactic dehydrogenase (S-LDH) in multiple myeloma. Eur J Clin Invest 1987;17:336-339.
3. Dimopoulus MA, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 1991;115:931-935.
4. Gkotzamandou M, Kastritis E, Gavriatopoulou MR, Nikitas N, Gika D, Mparmparousi D, Matsouka C, Terpos E, Dimopoulos MA. Increased serum lactate dehydrogenase should be included among the variables that define veryhigh- risk multiple myeloma. Clin Lymphoma Myeloma Leuk 2011;11:409-412.
5. Sanal SM, Yaylaci M, Mangold KA, Pantazis CG. Extensive extramedullary disease in myeloma. An uncommon variant with features of poor prognosis and dedifferentiation. Cancer 1996;77:1298-1302.
6. Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimopasi S, Parcharidou A, Kartasis Z, Zomas A, Symeonidis A, Viniou NA, Anagnostopoulos N, Economopoulos T, Zervas K, Dimipoulos MA. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol 2010;85;114-119.
7. Suguro M, Kanda Y, Yamamato R, Chizuka A, Hamaki T, Matsuyama T, Takezako N, Miwa A, Togawa A. High serum lactate dehyrdogenase level predicts short survival after vincristine-doxorubicin, dexamethasone (VAD) salvage for refractory multiple myeloma. Am J Hematol 2000;65:132-135.
8. Drent M, Cobben NAM, Hnderson RF, Wouters EFM, Diejen-Visser M. Usefulness of lactate dehyrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 1996;9:1736-1742.
9. Lott JA, Nemensanszky E. Lactate dehydrogenase. In: Lott JA, Wolf PL, eds. Clinical Enzymology, a case-orianted Aprroach 1987. p. 213-244.
10. Patel PS, Adhvaryu SG, Balar DB. Serum lactate dehydrogenase and its isoenzymes in leukemia patients: possible role in diagnosis and treatment monitoring. Neoplasma 1994;41:55-59.